Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Moves MDUFA V Meeting To May

Executive Summary

The US agency has pushed to next month a public meeting on the latest incarnation of the Medical Device User Fee Amendments. The meeting will be held remotely.

You may also be interested in...



MDUFA Meeting Postponed Again Due To COVID-19, This Time Indefinitely

The COVID-19 crisis had already forced the US FDA to postpone its first public meeting on the medical device user-fee negotiations to early next May, which was to be webcast. Now the agency has postponed the meeting indefinitely.

What COVID-19? FDA’s CDRH Sets June In-Person Meeting For Eye Implant Device

The US agency’s Center for Devices and Radiological Health is assembling an in-person advisory committee meeting in early June, the first since the COVID-19 pandemic began. The goal is to discuss the approval of an implant device to treat the natural aging of the eye.

FDA May Webcast First MDUFA Meeting, Postpone Or Cancel Others

The FDA says it is looking to webcast the upcoming 7 April MDUFA user fee public meeting, which is slated to be one of the most important agency meetings of the year. The decision comes in light of difficulties holding in-person meetings as the US grapples with the ongoing coronavirus crisis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel